Get started
Travere Therapeutics, Inc.Travere Therapeutics, Inc.Travere Therapeutics, Inc.

Travere Therapeutics, Inc.

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

TVTX chart


Full chart

TVTX upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.50 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.56 USD
Net income (FY)
‪−337.40 M‬ USD
Revenue (FY)
‪145.24 M‬ USD
Shares float
‪85.74 M‬
Beta (1Y)
1.37

Employees


Employees (FY)
380
Change (1Y)
−82 −17.75%
Revenue / Employee (1Y)
‪382.21 K‬ USD
Net income / Employee (1Y)
‪−990.35 K‬ USD

About Travere Therapeutics, Inc.


Sector
Health Technology
CEO
Eric M. Dube
Headquarters
San Diego
Website
travere.com
Founded
2008
FIGI
BBG000P9D6W9
Travere Therapeutics, Inc. is a biopharmaceutical company. It engages in the identification, development, commercialization, and distribution of therapies to people living with rare diseases. The firm's products include Chenodal, Cholbam, and Thiola. The company was founded by Martin Shkreli on February 7, 2008 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

TVTX news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

TVTX highest yielding bonds


RTRX4685732
Travere Therapeutics, Inc. 2.5% 15-SEP-2025
Yield to maturity
3.82%
Maturity date
Sep 15, 2025
RTRX5376243
Travere Therapeutics, Inc. 2.25% 01-MAR-2029
Yield to maturity
3.47%
Maturity date
Mar 1, 2029

Explore more bonds 

Frequently Asked Questions


The current price of TVTX is 17.37 USD — it has increased by 0.43% in the past 24 hours. Watch Travere Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Travere Therapeutics, Inc. stocks are traded under the ticker TVTX.
TVTX stock has risen by 1.37% compared to the previous week, the month change is a −7.44% fall, over the last year Travere Therapeutics, Inc. has showed a 84.20% increase.
We've gathered analysts' opinions on Travere Therapeutics, Inc. future price: according to them, TVTX price has a max estimate of 42.00 USD and a min estimate of 18.00 USD. Watch TVTX chart and read a more detailed Travere Therapeutics, Inc. stock forecast: see what analysts think of Travere Therapeutics, Inc. and suggest that you do with its stocks.
TVTX reached its all-time high on Aug 15, 2003 with the price of 765.00 USD, and its all-time low was 0.18 USD and was reached on Jul 25, 2008. View more price dynamics on TVTX chart.
See other stocks reaching their highest and lowest prices.
TVTX stock is 3.14% volatile and has beta coefficient of 1.37. Track Travere Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Travere Therapeutics, Inc. there?
Today Travere Therapeutics, Inc. has the market capitalization of ‪1.50 B‬, it has increased by 1.60% over the last week.
Yes, you can track Travere Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Travere Therapeutics, Inc. is going to release the next earnings report on Mar 3, 2025. Keep track of upcoming events with our Earnings Calendar.
TVTX earnings for the last quarter are −0.70 USD per share, whereas the estimation was −0.67 USD resulting in a −4.61% surprise. The estimated earnings for the next quarter are −0.64 USD per share. See more details about Travere Therapeutics, Inc. earnings.
Travere Therapeutics, Inc. revenue for the last quarter amounts to ‪62.90 M‬ USD, despite the estimated figure of ‪60.87 M‬ USD. In the next quarter, revenue is expected to reach ‪71.08 M‬ USD.
TVTX net income for the last quarter is ‪−54.81 M‬ USD, while the quarter before that showed ‪−70.41 M‬ USD of net income which accounts for 22.15% change. Track more Travere Therapeutics, Inc. financial stats to get the full picture.
No, TVTX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 380.00 employees. See our rating of the largest employees — is Travere Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Travere Therapeutics, Inc. EBITDA is ‪−236.37 M‬ USD, and current EBITDA margin is −232.87%. See more stats in Travere Therapeutics, Inc. financial statements.
Like other stocks, TVTX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Travere Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Travere Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Travere Therapeutics, Inc. stock shows the neutral signal. See more of Travere Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.